FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a crystalline form of I (R)-4-amino-1-(1-(but-2-inoyl)pyrrolidin-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1H-pyrrolo[2,3-d]pyridazin-7(6H)-one, having X-ray powder diffractometry spectrum obtained by means of Cu-Ka radiation and represented by angle 2θ and interplane distance, which has characteristic peaks at 2θ±0.2: 9.91, 12.20, 17.24, 17.64 and 21.48. Invention also relates to a method of producing crystalline form I, to a pharmaceutical composition, to use.
EFFECT: obtaining a stable crystalline form of I(R)-4-amino-1-(1-(but-2-inoyl)pyrrolidin-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1H-pyrrolo[2,3-d]pyridazin-7(6H)-one, having properties of Bruton's tyrosine kinase inhibitor.
7 cl, 4 dwg, 2 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SODIUM SALT OF THE URIC ACID TRANSPORTER INHIBITOR AND ITS CRYSTALLINE FORM | 2016 |
|
RU2719484C2 |
| P-TOLUENESULPHONATE FOR MEK KINASE INHIBITOR AND CRYSTALLINE FORM THEREOF, AND METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2704251C2 |
| JAK INHIBITOR AND METHOD OF ITS OBTAINING | 2019 |
|
RU2812575C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARATION | 2018 |
|
RU2767872C2 |
| PHENYLPYRIDAZINE COMPOUNDS AND MEDICINAL AGENTS COMPRISING THEREOF | 2001 |
|
RU2269519C2 |
| SUBSTITUTED PYRROLO [2,3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3,4-D] PYRIDAZIN-4-ONES AS PROTEINKINASE INHIBITORS | 2017 |
|
RU2749038C2 |
| STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | 2005 |
|
RU2330845C1 |
| CRYSTALLINE AND SALT FORMS OF THE TGF-βR1 INHIBITOR AND THE METHOD OF OBTAINING THEM | 2018 |
|
RU2750702C1 |
| AMINOPIRIDAZINOVE COMPOUNDS AS PROTEINKINASE INHIBITORS | 2014 |
|
RU2674701C2 |
| CRYSTALLINE FORM OF INHIBITOR BISULPHATE JAK AND METHOD FOR PRODUCTION THEREOF | 2015 |
|
RU2704795C2 |
